Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Rationale: Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (del19 or L858R) show an impressive progression-free survival between 9 and 11 months when treated with gefitinib. Combination of gefitinib and berberine could improve efficacy in lung cancer with EGFR mutation in vivo and vitro. The investigators hypothesize that progression-free survival could be improved by combination of gefitinib and berberine.
Epistemonikos ID: 3897df9679c16be80c77a39f164ac02000350b34
First added on: May 21, 2024